UBS Group Issues Pessimistic Forecast for Evolent Health (NYSE:EVH) Stock Price

Evolent Health (NYSE:EVH) had its target price reduced by investment analysts at UBS Group from $10.00 to $5.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the technology company’s stock. UBS Group’s price objective indicates a potential upside of 53.14% from the stock’s previous close.

EVH has been the topic of a number of other reports. KeyCorp cut shares of Evolent Health from an “overweight” rating to a “sector weight” rating in a research note on Wednesday. Canaccord Genuity Group lowered their price target on Evolent Health from $16.00 to $9.00 and set a “buy” rating for the company in a report on Friday, November 14th. Royal Bank Of Canada dropped their price objective on Evolent Health from $5.00 to $3.00 and set a “sector perform” rating for the company in a research report on Wednesday. Zacks Research upgraded Evolent Health from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th. Finally, Oppenheimer lowered their target price on Evolent Health from $18.00 to $12.00 and set an “outperform” rating for the company in a research note on Wednesday, November 12th. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $6.65.

Evolent Health Price Performance

Shares of NYSE EVH traded up $0.13 during mid-day trading on Thursday, reaching $3.27. The company had a trading volume of 2,610,300 shares, compared to its average volume of 3,079,596. The firm has a market cap of $364.37 million, a price-to-earnings ratio of -0.64 and a beta of 0.27. The business’s 50-day simple moving average is $3.52 and its 200 day simple moving average is $5.85. Evolent Health has a one year low of $2.50 and a one year high of $12.06. The company has a debt-to-equity ratio of 1.25, a quick ratio of 1.33 and a current ratio of 1.33.

Evolent Health (NYSE:EVH) last announced its quarterly earnings data on Tuesday, February 24th. The technology company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. The firm had revenue of $468.72 million for the quarter, compared to the consensus estimate of $468.48 million. Evolent Health had a negative net margin of 28.49% and a positive return on equity of 1.30%. The business’s revenue for the quarter was down 27.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.02) earnings per share. On average, research analysts predict that Evolent Health will post 0.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Evolent Health

Several large investors have recently bought and sold shares of the company. Durable Capital Partners LP bought a new stake in shares of Evolent Health in the 2nd quarter valued at $72,326,000. Rubicon Founders LLC bought a new stake in Evolent Health during the third quarter valued at $49,204,000. 8 Knots Management LLC bought a new stake in Evolent Health during the second quarter valued at $32,802,000. Eventide Asset Management LLC grew its holdings in Evolent Health by 54.0% during the 3rd quarter. Eventide Asset Management LLC now owns 6,292,511 shares of the technology company’s stock worth $53,246,000 after acquiring an additional 2,205,659 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in shares of Evolent Health by 162.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,836,402 shares of the technology company’s stock worth $26,861,000 after acquiring an additional 1,754,520 shares in the last quarter.

Key Evolent Health News

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Q4 results topped expectations — Evolent reported $0.08 EPS vs. $0.06 consensus and revenue of $468.7M (in line). The beat and the company’s commentary on execution are a near-term bullish trigger. Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results (PR Newswire)
• Positive Sentiment: Earnings call highlighted strong oncology growth and strategic wins — management pointed to market-share gains, strong renewal rates and continued migration to enhanced Performance Suite contracts, supporting medium-term revenue opportunities. Q4 2025 Earnings Call Transcript (Seeking Alpha)
• Positive Sentiment: BTIG left a buy rating and set a new $8.00 target (down from $10) — still implies significant upside versus current levels and signals at least one institutional view that upside remains after the quarter. BTIG Research price target note
• Neutral Sentiment: FY2026 revenue guidance of $2.4B–$2.6B was provided and sits around consensus — the range keeps expectations steady but does not materially change the near-term story. FY2026 guidance in PR
• Neutral Sentiment: Headline coverage notes a sharp intraday move — media and retail attention (e.g., Yahoo Finance) likely amplified trading volume and the price bounce. That can produce short-term spikes without changing fundamentals. Evolent Health Shares Skyrocket (Yahoo Finance)
• Negative Sentiment: Royal Bank of Canada cut its target to $3.00 and moved to “sector perform” — this downgrade to a lower target adds selling pressure and signals more cautious institutional views. RBC price target note
• Negative Sentiment: Needham sharply cut its target from $15 to $4 while keeping a buy — the large reduction reduces the peg for upside and suggests lowered expectations for near-term recovery. Needham price target note
• Negative Sentiment: KeyCorp downgraded EVH from overweight to sector weight — another institutional shift toward caution that can weigh on sentiment and limit short-term rallies. Analyst downgrade coverage (TickerReport)

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.